 Monopar Therapeutics Inc. Monopar or the Company MNPR, a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2019 financial results and business updates. In December 2019, the Company completed its initial public offering of 1,277,778 shares of common stock, including the underwriters exercise of their over-allotment option, at a public offering price of 8.00 per share before underwriting discounts and commissions. 